<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: There is a need for more exhaustive data concerning the use of prophylactic ureteral stenting for extended debulking and cytoreductive procedures in the literature </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: A retrospective analysis of the CARPEPACEM study protocol database was performed </plain></SENT>
<SENT sid="2" pm="."><plain>The trial protocol schedules the positioning of bilateral ureteral stents before cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Fifty-one operated patients: 31 (59.6%) with peritoneal dissemination from <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, 8 (15.3%) from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 4 (7.9%) from <z:mpath ids='MPATH_303'>pseudomyxoma peritonei</z:mpath>, 3 (5.7%) from <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, 2 (3.8%) from <z:hpo ids='HP_0100003'>peritoneal mesothelioma</z:hpo>, 1 (1.9%) from <z:e sem="disease" ids="C0496779" disease_type="Neoplastic Process" abbrv="">appendiceal cancer</z:e>, 1 (1.9%) from <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e>, and 1 (1.9%) from <z:hpo ids='HP_0100243'>leiomyosarcoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Mean and median <z:e sem="disease" ids="C0153467" disease_type="Neoplastic Process" abbrv="">peritoneal cancer</z:e> index: 11 and 10 (range: 0-28) </plain></SENT>
<SENT sid="5" pm="."><plain>CC-score: CC-0 in 45 (86.5%) patients, CC-1 in 5 (9.6%) and CC-2 in 1 (1.9%) </plain></SENT>
<SENT sid="6" pm="."><plain>HIPEC was performed with <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> + <z:chebi fb="6" ids="45863">taxol</z:chebi> in 22 patients (42.3%), <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> + adriablastin in 10 (19.2%), <z:chebi fb="0" ids="25357">mitomycin</z:chebi> in 9 (17.3%), <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> + <z:chebi fb="0" ids="25357">mitomycin</z:chebi> in 7 (13.4%), <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> + <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> in 2 (3.8%), and <z:chebi fb="6" ids="45863">taxol</z:chebi> + adriablastin in 1 (1.9%) </plain></SENT>
<SENT sid="7" pm="."><plain>Two major ureteral complications were observed (3.9%) </plain></SENT>
<SENT sid="8" pm="."><plain>DISCUSSION: Prophylactic ureteral stenting could reduce the risk of postoperative ureteral complications without an increase in stent placement-related complications; however, a randomized clinical trial is needed </plain></SENT>
</text></document>